$15.5MSeed, 22 February 2026
Funds expansion of the mcPCR platform, clinical workflows and Cambridge R&D.
- Amount
- $15.5M
- Stage
- Seed
- Announced
- 22 February 2026
- Lead
- ARCH Venture Partners
- Other investors
- +ND Capital, OMX Ventures, Meltwind Advisory
- Use of funds
- Funds expansion of the mcPCR platform, clinical workflows and Cambridge R&D.
- Checked
- Announced by the company
- Sources
- Syndex Bio unveils mcPCR technology following seed financing pharmiweb.com
Syndex Bio unveils mcPCR technology following seed financing news-medical.net